Non-Small Cell Lung Cancer Pipeline Insight: Novel therapies in the pipeline 2017-30

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Pipeline Insight: Novel therapies in the pipeline 2017-30

May 01
11:50 2020
Non-Small Cell Lung Cancer Pipeline Insight: Novel therapies in the pipeline 2017-30

Non-Small Cell Lung Cancer Pipeline
According to DelveInsight, Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030. The total therapeutic market of Non-Small Cell Lung Cancer in seven major markets was found to be USD 9,730 million in 2017 which is expected to increase during the study period (2017-2030).

Non-Small Cell Lung Cancer Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces in-depth Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the Non-Small Cell Lung Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.

Non-Small Cell Lung Cancer Emerging Drugs

  • Nazartinib/EGF816: Novartis Pharmaceuticals
  • Capmatinib/INC280: Novartis Pharmaceuticals
  • Telisotuzumab Vedotin: AbbVie
  • JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
  • Ensartinib/X-396: Xcovery
  • Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
  • SAR408701: Sanofi
  • Braftovi/encorafinib + Mektovi/binimetinib: Pfizer, and others.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

According to DelveInsight, Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Non-Small Cell Lung Cancer in seven major markets was found to be USD 9,730 million in 2017 which is expected to increase during the study period (2017–2030).

Request for sample pages

Scope of the report

  • The Non-Small Cell Lung Cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Small Cell Lung Cancer across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Non-Small Cell Lung Cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Non-Small Cell Lung Cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Small Cell Lung Cancer.

Visit to know more.

Table of contents

1. Report Introduction

2. Non-Small Cell Lung Cancer 

3. Non-Small Cell Lung Cancer Current Treatment Patterns

4. Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Small Cell Lung Cancer Late Stage Products (Phase-III)

7. Non-Small Cell Lung Cancer Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Small Cell Lung Cancer Discontinued Products

13. Non-Small Cell Lung Cancer Product Profiles

14. Non-Small Cell Lung Cancer Key Companies

15. Non-Small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Non-Small Cell Lung Cancer Unmet Needs

18. Non-Small Cell Lung Cancer Future Perspectives

19. Non-Small Cell Lung Cancer Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Related Articles

Categories